Kevin Tang Acquires 200,000 Shares of Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) Stock

Key Points

• Kevin Tang, the Director of Aurinia Pharmaceuticals, acquired 200,000 shares of the company at an average price of $11.68 per share, totaling $2.34 million and increasing his ownership by 1.80%.
• Aurinia Pharmaceuticals reported quarterly earnings of $0.16 per share, missing analysts' expectations, but had a revenue of $70.01 million, exceeding projections of $64.27 million.
• Institutional investors hold approximately 36.83% of Aurinia's stock, with recent activity indicating growing interest among hedge funds in the biotechnology company.

Aurinia Pharmaceuticals Inc (NASDAQ:AUPH - Get Free Report) TSE: AUP Director Kevin Tang acquired 200,000 shares of Aurinia Pharmaceuticals stock in a transaction dated Tuesday, August 5th. The stock was bought at an average price of $11.68 per share, with a total value of $2,336,000.00. Following the completion of the purchase, the director directly owned 11,329,500 shares in the company, valued at $132,328,560. This represents a 1.80% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through the SEC website.

Kevin Tang also recently made the following trade(s):

• On Monday, August 4th, Kevin Tang purchased 100,000 shares of Aurinia Pharmaceuticals stock. The stock was bought at an average price of $11.34 per share, with a total value of $1,134,000.00.
• On Friday, August 1st, Kevin Tang acquired 1,000,000 shares of Aurinia Pharmaceuticals stock. The shares were bought at an average cost of $10.12 per share, for a total transaction of $10,120,000.00.

Aurinia Pharmaceuticals Price Performance

Shares of NASDAQ AUPH traded up $0.25 during mid-day trading on Tuesday, reaching $11.70. The company's stock had a trading volume of 3,144,408 shares, compared to its average volume of 1,573,970. The firm has a market capitalization of $1.54 billion, a PE ratio of 27.21 and a beta of 1.23. The company has a debt-to-equity ratio of 0.18, a current ratio of 5.23 and a quick ratio of 4.63. The stock has a fifty day moving average of $8.49 and a two-hundred day moving average of $8.18. Aurinia Pharmaceuticals Inc has a 52 week low of $5.20 and a 52 week high of $11.80.

Aurinia Pharmaceuticals (NASDAQ:AUPH - Get Free Report) TSE: AUP last released its quarterly earnings data on Thursday, July 31st. The biotechnology company reported $0.16 earnings per share for the quarter, missing analysts' consensus estimates of $0.17 by ($0.01). The business had revenue of $70.01 million during the quarter, compared to the consensus estimate of $64.27 million. Aurinia Pharmaceuticals had a return on equity of 20.06% and a net margin of 23.31%. As a group, sell-side analysts anticipate that Aurinia Pharmaceuticals Inc will post 0.11 EPS for the current fiscal year.

Hedge Funds Weigh In On Aurinia Pharmaceuticals

Hedge funds have recently made changes to their positions in the business. GF Fund Management CO. LTD. bought a new position in shares of Aurinia Pharmaceuticals in the fourth quarter worth about $27,000. Tower Research Capital LLC TRC boosted its stake in Aurinia Pharmaceuticals by 368.5% during the fourth quarter. Tower Research Capital LLC TRC now owns 3,350 shares of the biotechnology company's stock valued at $30,000 after buying an additional 2,635 shares during the last quarter. Vermillion & White Wealth Management Group LLC bought a new position in Aurinia Pharmaceuticals during the fourth quarter valued at approximately $31,000. GAMMA Investing LLC boosted its stake in Aurinia Pharmaceuticals by 56.1% during the first quarter. GAMMA Investing LLC now owns 4,852 shares of the biotechnology company's stock valued at $39,000 after buying an additional 1,744 shares during the last quarter. Finally, MAI Capital Management bought a new position in Aurinia Pharmaceuticals during the first quarter valued at approximately $39,000. Institutional investors own 36.83% of the company's stock.

Analyst Ratings Changes

Several equities research analysts recently issued reports on AUPH shares. Royal Bank Of Canada increased their target price on shares of Aurinia Pharmaceuticals from $8.00 to $9.00 and gave the stock an "outperform" rating in a report on Friday. HC Wainwright reissued a "buy" rating and issued a $17.00 target price on shares of Aurinia Pharmaceuticals in a report on Wednesday, July 30th.

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.